Background: Traditional Chinese medicine (TCM) has demonstrated considerable clinical efficacy in treating coronavirus disease 2019 (COVID-19). Puping Qinghua prescription (PPQH), a traditional Chinese medicine formulation, was found to be effective against clinical symptoms in patients with Omicron variant virus infection, Nonetheless, its safety and mechanism are unclear. Purpose: To provide evidence of validity and adverse events associated with PPQH in treating SARS-CoV-2 Omicron variants infection. Methods: Four hundred and eighty patients diagnosed with COVID-19 were randomised into the PPQH group (n = 240) and the LLQW group (n = 240). Basic information such as age, sex, vaccination status, symptoms, etc were registered. Laboratory tests for 142 patients, including cytokine levels and lymphocyte counts, liver and kidney function. Results: After intervention, levels of NK cells, IFN-alpha, IL-5, IL-6, and IL-12p70 were reduced in the PPQH group, whereas the levels of TNF-alpha, IL-1 beta, IL-4, IL-6, and IL-17A were reduced in the Lianhua Qingwen (LHQW) group (P < 0.05). PPQH was more effective in shortening duration of fever and reducing degree of cough compared with LHQW (P < 0.05). Liver and kidney functions remained unimpaired before and after intervention in both groups (P > 0.05). In addition, the incidence of adverse reactions such as palpitations, dizziness and sweating was lower in the PPQH group (P < 0.05). Conclusion: The efficacy of PPQH is comparable to LHQW in patients infected with Omicron variant virus. More excitingly, PPQH demonstrates a higher level of security.

OBJECTIVE:To investigate the antipyretic effect of early treatment with Traditional Chinese Medicine (TCM) on coronavirus disease 2019 (COVID-19) patients. METHODS:We retrospectively analyzed 369 patients from January 26th, 2020 to April 15th, 2020, who had been diagnosed with COVID-19. Among 92 eligible cases, 45 cases were identified as treatment group Ⅰ ( 45) and 47 cases were identified as treatment group Ⅱ. Patients in the treatment group Ⅰ were treated with TCM herbal decoction within 5 d after admission. Patients in the treatment group Ⅱ were treated with TCM herbal decoction after the 6th admission day. The onset time of antipyretic effect, the antipyretic time, the time of negative oropharyngeal swab nucleic acid conversion, and the changes of cell count in blood routine test were compared. RESULTS:The treatment group I showed shorter average antipyretic duration (4 7 d; <0.05), and shorter average time for polymerase chain reaction (PCR) nucleic acid test results to turn negative (7 11 d; <0.05) than the treatment group II. For patients ( 54) with body temperature>38 ℃, patients in the treatment group I had shorter median onset time of antipyretic effect than those in the treatment group II (3 4 d; <0.05). The absolute lymphocyte (LYMPH) count and absolute eosinophil (EOS) count on the 3rd day after admission and the neutrophil/lymphocyte ratio on the 6th day after admission of patients in the treatment group I were notably different from those in the treatment group II at the same time point (0.05). Based on Spearman's rank correlation analysis, the change of body temperature on the 3rd day after admission was positively correlated with the increase of EOS count and the increase of EOS count and LYMPH counts on the 6th day after admission (0.01). CONCLUSIONS:Early TCM intervention within 5 d after hospital admission shortened the onset time of antipyretic effect and fever duration of COVID-19 patients, reduced the time required for PCR test results to turn negative. Moreover, early TCM intervention also improved the results of inflammatory markers for COVID-19 patients. LYMPH and EOS counts can be used as indicators of TCM antipyretic effect.

Objectives:We previously revealed that scorpio and centipede (SC) improve the inflammatory response in asthma, whereas it is unclear whether ferroptosis is involved in this process.Materials and Methods:The asthmatic mouse model was established and lung tissues were collected for histopathological examination. The levels of tumor necrosis factor-α (TNF-α), interleukin- (IL-)1β, Fe2+, malondialdehyde (MDA), glutathione peroxidase 4 (GPX4), ferritin heavy chain 1(FTH1), and reactive oxygen species (ROS) were assessed in asthmatic mice and mouse airway epithelial cells.Results:Our results showed that ferroptosis was induced in asthmatic mice, as evidenced by the reduction of FTH1 and GPX4 expression and the increase of MDA and Fe2+ levels (all P<0.05). Ferrostatin-1 repressed inflammation and ferroptosis of asthmatic mice. Additionally, SC significantly inhibited the levels of TNF-α, IL-1β, MDA, and Fe2+, while enhancing FTH1 and GPX4 expression. However, SC plus erastin showed the reverse results. Moreover, ferroptosis remarkably increased in asthmatic airway epithelial cells, while SC suppressed ferroptosis of the cells (all P<0.05).Conclusion:SC ameliorated asthma by inhibiting the crosstalk between ferroptosis and inflammation in airway epithelial cells.

KeChuanLiuWei‐Mixture (KCLW) is widely used as a Chinese medicine prescription to treat severe asthma. However, the underlying therapeutic mechanism of KCLW remains unclear. In this study, a network pharmacology method was used to identify the chemical constituents of KCLW by the TCMSP database and ultra‐performance liquid chromatography coupled with time‐of‐flight mass spectrometry. Differential expression identification, protein–protein interaction (PPI) network and functional enrichment analysis were used to screen key targets of KCLW for severe asthma. Our results confirmed that quercetin, luteolin, kaempferol, and wogonin are the most critical active ingredients in KCLW. Moreover, the 16 relevant severe asthma‐related targets of KCLW were obtained by overlapping the PPI networks of the KCLW putative targets and severe asthma‐related genes, among which the most important targets were IL‐6, NOS2, VEGFA, CXCL2, and PLAT. Functionally, the 16‐targets and their interacting differentially expressed genes were primarily related to biological functions and pathways related to immunity and inflammation, such as inflammatory response, T cell differentiation, Nrf2/HO‐1 signaling pathway, TGF‐β/Smad signaling pathway, and NF‐κB signaling pathway. KCLW inhibited inflammation in PDGF‐BB‐induced airway smooth muscle cells. In summary, this study demonstrates the active substance and potential therapeutic mechanism of KCLW in severe asthma, and offers a clinical direction for KCLW against severe asthma.

目的 采用网络药理学和分子对接技术探讨温阳抗寒汤治疗支气管哮喘的潜在作用机制.方法 基于中药系统药理学数据库与分析平台TCMSP获取温阳抗寒汤有效活性成分及其靶点,通过GeneCards、OMIM、PharmGKB、TTD、DrugBank数据库获取哮喘相关靶点,将药物靶点与疾病靶点映射得到温阳抗寒汤治疗支气管哮喘的预测靶点.使用Cytoscape软件绘制药物活性成分-靶点网络图,使用String数据库构建蛋白互作网络,使用R语言进行GO富集分析和KEGG通路富集分析,预测温阳抗寒汤治疗支气管哮喘的作用机制,使用AutoDockTools、Autodock vina、Pymol软件进行分子对接预测和部分对接结果可视化.结果 筛选得到温阳抗寒汤作用于支气管哮喘的有效活性成分115个,检索得到支气管哮喘相关的靶点4802个,温阳抗寒汤与支气管哮喘的交集靶点86个,关键有效成分包括槲皮素、山奈酚、木犀草素、汉黄芩素、黄芩苷、柚皮素等,涉及的核心靶点包括HIF1A、TP53、AKT1、ESR1等.通过GO分析(P<0.05)得到GO条目1866个,其中包括生物过程(BP)条目1672个,细胞组成(CC)43个,分子功能(MF)条目151个,涉及细胞外刺激的反应、对异型生物质刺激等.KEGG通路富集(P<0.05)得到通路149条,其中P53信号通路、IL-17信号通路、PI3K-Akt信号通路、TNF信号通路可能为治疗支气管哮喘的潜在信号通路.将涉及的核心靶点与中药活性成分进行分子对接,结果显示温阳抗寒汤的有效活性成分与选定的支气管哮喘的靶点均有较好的结合活性.结论 温阳抗寒汤主要通过HIF1A、TP53、AKT1、ESR1等靶点作用于P53信号通路、IL-17信号通路、PI3K-Akt信号通路、TNF信号通路等通过减轻气道炎症反应、抑制气道重塑等发挥治疗作用.

Background: Coronavirus disease (COVID-19) seriously endangers global public health. Pupingqinghua prescription (PPQH) is an herbal formula from traditional Chinese medicine used for treatment of SARS-CoV-2 infection. This study aims to evaluate the clinical efficacy and safety of PPQH in Chinese participants infected with the SARS-CoV-2 Omicron variant. Methods: A total of 873 SARS-CoV-2 (Omicron)-infected patients were included. Among them, the patients were divided into the PPQH group (653 cases) and LHQW group (220 cases) according to different medications. The effectiveness indicators (hematological indicators, Ct values of novel Coronavirus nucleic acid tests, and viral load-shedding time) and safety indicators (liver and kidney function and adverse events) were analyzed. Results: There was no significant difference in baseline characteristics between the PPQH group and the LHQW group, except the gender; After the treatment, the levels of IL-5, IL-6, IL-10, NK cells, and INF-α of the patients in the PPQH group showed a downward trend (p < 0.05); The viral load shedding time was 5.0 (5.0, 7.0) in the PPQH group and 5.0 (4.0, 7.0) in the LHQW group; both PPQH and LHQW can shorten the duration of symptoms of fever, cough, and sore throat. The re-positive rate of COVID-19 test was 1.5 % in the PPQH group and 2.3 % in the LHQW group. In terms of safety, the levels of γ-GTT decreased significantly (p < 0.01); gastrointestinal reaction was the primary adverse reaction, and the reaction rate was 4.7 % in the PPQH group and 9.5 % in the LHQW group. Conclusion: PPQH can shorten the length of hospital stay and improve clinical symptoms of patients with SARS-COV-2 (Omicron), and it also has a good safety profile.

Asthma is one of the most common chronic inflammatory diseases. Although the scorpion and centipede (SC) significantly ameliorates asthma and changes exosomal miRNAs, the molecular mechanism is still obscure. Here, we show that SC improves inflammation in asthmatic mice and increases M2 macrophage-derived exosomes (M2Φ-Exos) by promoting M2 macrophage polarization. The M2Φ-Exos remarkably inhibits airway epithelial cell pyroptosis by reducing the expression of NLRP3, caspase-1, and LI-1β and mitochondrial swelling. Furthermore, miR-30b-5p is up-regulated in M2Φ-Exos compared with M1Φ-Exos. Overexpression of miR-30b-5p in M2Φ-Exos prevents airway epithelial cell pyroptosis, while down-regulation of miR-30b-5p promotes pyroptosis. We also uncover that pyroptosis is increased in asthmatic mice, while SC blocks pyroptosis. Moreover, miR-30b-5p overexpressed M2Φ-Exos further enhances the ameliorative effect of SC, which significantly down-regulates IRF7 expression. Our results collectively reveal that M2Φ-Exos induced by SC could carry miR-30b-5p to mitigate severe asthma by inhibiting airway epithelial cell pyroptosis. Most importantly, our findings may provide a potential clinical application of M2Φ-Exos for treating severe asthma.

Purpose . The purpose of this study is to study the effects of heat-clearing Traditional Chinese Medicine (TCM) in the stable stage of bronchiectasis via N-of-1 trials. Methods . The N-of-1 trials in this study were randomized and double-blinded with crossover comparisons consisting of three pairs. Each pair was of two 4-week periods. Each patient took the individualized decoction in the experimental period and the individualized decoction was removed of heat-clearing drugs, mainly including heat-clearing and detoxifying drugs, in the control period for three weeks. After three weeks, the patients stopped taking the decoction for one week. The primary outcome was from patients’ self-reporting symptoms scores on a 1–7-point Likert scale. Mixed-effects models were used to conduct statistical analysis on these N-of-1 trials. Results . Of the 21 patients enrolled, 15 completed three pairs of N-of-1 trials (71.43%). (1) Seen from the individual level, no statistical difference between the experimental decoction and the control ( P   >  0.05) was observed. However, 5 patients found better decoctions according to the clinical criteria. (2) As revealed by the group data of all the N-of-1 trials, the control was better than the individualized decoction in terms of symptom scores on the Likert scale (1.94 ± 0.69 versus 2.08 ± 0.68, P  = 0.04, mean difference, and 95% CI: 0.19 (0.01, 0.37)) and on CAT scores (13.66 ± 6.57 versus 13.95 ± 6.97, P  = 0.04, mean difference, and 95% CI: 0.86 (0.042, 1.67)), but such differences were not clinically significant. The other outcomes, such as Likert scale score of respiratory symptoms and 24-hour sputum volume, showed no statistical difference. Conclusion . The experimental design of this study can make the TCM individualized treatment fully play its role and can detect the individualized tendencies according to the severity of phlegm and heat in some subjects. With the intermittent use or reduced use of heat-clearing drugs, most of the subjects, at the group level, enrolled in the series of N-of-1 trials may improve the symptoms and quality of life while saving the cost of TCM and reducing the potential side effects of heat-clearing TCM. This trial is registered with clinicaltrials.goc ( NCT03147443 ).

目的 探讨温阳抗寒汤联合西药治疗肾阳虚型慢性支气管炎急性发作患者的效果.方法 将114例慢性支气管炎急性发作患者随机分为对照组(n=59)和观察组(n=55),对照组给予常规西药治疗,观察组在对照组基础上给予温阳抗寒汤.比较2组临床疗效、中医证候评分、莱塞斯特咳嗽量表(LCQ)评分;分析2组白细胞介素-2受体(IL-2R)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-10(IL-10)的水平变化.结果 观察组总有效率为90.91％,高于对照组的86.44％,差异有统计学意义(P＜0.05).治疗后,观察组中医证候评分和IL-2R、IL-6、IL-8水平均低于对照组,差异有统计学意义(P＜0.05);观察组社会、心理、生理得分及LCQ总分均高于对照组,差异有统计学意义(P＜0.05).结论 温阳抗寒汤联合西药对肾阳虚型慢性支气管炎急性发作患者疗效较佳,可改善患者免疫水平,提高生活质量.

目的 探讨温阳抗寒汤治疗风寒犯肺型感染后咳嗽(PIC)的效果.方法 将110例风寒犯肺型PIC患者随机分为对照组和观察组,每组55例.对照组患者接受常规治疗,观察组患者在对照组基础上服用温阳抗寒汤.比较2组治疗前后咳嗽积分、咳嗽程度、证候总积分和肿瘤坏死因子(TNF)、C反应蛋白(CRP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)水平.结果 观察组总有效率高于对照组,差异有统计学意义(P＜0.05).观察组治疗后咳嗽积分、咳嗽程度、证候总积分和TNF、CRP、IL-6、IL-8水平均低于对照组,差异有统计学意义(P＜0.05).观察组咳嗽、咯痰、畏寒、乏力症状消失例数多于对照组,差异有统计学意义(P＜0.05).观察组不良反应发生率为10.91％,对照组不良反应发生率为12.73％,差异无统计学意义(P＞0.05).结论 温阳抗寒汤可有效缓解风寒犯肺型PIC患者的咳嗽症状,减轻咳嗽的严重程度,降低气道炎症反应水平,调节机体免疫水平.

日的 观察温阳补肾填精膏方对低剂量吸人性糖皮质激素维持治疗的哮喘患者激素撤停的影响.方法 将140例低剂量吸人性糖皮质激素维持治疗的哮喘患者随机分为治疗组(71例)、对照组(69例).对照组人组后即停用激素,治疗组停用激素的同时加用有温阳补肾填精功效的膏方,膏方服用时间为8周;从病例纳入当天开始计算,共计随访16周.观察比较治疗失败率,以及哮喘症状发生次数、缓解药物用量、哮喘控制测试评分表(ACT)评分、呼气峰流速(PEF)、第一秒用力呼吸量(FEV1)、FEV1实测值占预计值百分比(FEV1％)的变化情况.结果 ①治疗组、对照组治疗失败率分别为8.45％、24.64％,治疗组治疗失败率低于对照组(P＜0.01).②与激素撤停前比较,治疗组患者激素撤停后每周日间症状发生次数、每周缓解药物用量增多(P＜0.05),对照组患者激素撤停后每周日间症状发生次数、每周夜间症状发生次数、每周活动受限次数、每周缓解药物用量增多(P＜0.05);激素撤停后组间比较,治疗组患者每周日间症状发生次数、每周夜间症状发生次数、每周活动受限次数及每周缓解药物用量少于对照组(P＜0.01).③与激素撤停前比较,治疗组患者激素撤停后ACT评分降低(P＜0.01);对照组患者激素撤停后ACT评分及PEF、FEV1、FEV1％值降低(P＜0.01);激素撤停后组间比较,治疗组ACT评分及PEF、FEV1、FEV1％值高于对照组(P＜0.01).结论 温阳补肾填精膏方有助于低剂量吸人性糖皮质激素维持治疗的哮喘患者撤停激素.

Background. Our previous studies showed that N-of-1 trials could reflect the individualized characteristics of traditional Chinese medicine (TCM) syndrome differentiation with good feasibility, but the sensitivity was low. Therefore, this study will use hierarchical Bayesian statistical method to improve the sensitivity and applicability of N-of-1 trials of TCM. Methods/Design. This is a randomized, double-blind, placebo-controlled, three-pair crossover trial for a single subject, including 4–8 weeks of run-in period and 24 weeks of formal trial. In this study, we will recruit a total of 30 participants who are in the stable stage of bronchiectasis. The trial will be divided into three pairs (cycles), and one cycle contains two observation periods. The medications will be taken for three weeks and stopped for one week in the last week of each observation period. The order of syndrome differentiation decoction and placebo will be randomly determined. Patient self-reported symptom score (on a 7-point Likert scale) is the primary outcome. Discussion. Some confounding variables (such as TCM syndrome type and potential carryover effect of TCM) will be introduced into hierarchical Bayesian statistical method to improve the sensitivity and applicability of N-of-1 trials of TCM, and the use of prior available information (e.g., “borrowing from strength” of previous trial results) within the analysis may improve the sensitivity of the results of a series of N-of-1 trials, from both the individual and population level to study the efficacy of TCM syndrome differentiation. It is the exploration of improving the objective evaluation method of the clinical efficacy of TCM and may provide reference value for clinical trials of TCM in other chronic diseases. This trial is registered with ClinicalTrials.gov (ID: NCT04601792).

Based on the classical literature of traditional Chinese medicine (TCM) and reflections on clinical practice, we intend to explain the etiology, pathogenesis, law of transmission and change, as well as therapeutic prescriptions of coronavirus disease 2019 (hereinafter referred to as COVID-19) based on the theory of “damp epidemic” We reckon that COVID-19 is caused by the endogenous damp toxin and exogenous epidemic pathogens, which interact with each other and contribute to the disease together;COVID⁃19 pandemic not only follows the law of transmission and change of Wei-Qi-Ying-Xue, but also shows the transmission and change process within triple energizers Besides, we also put forward clinical suggestions for the TCM diagnosis and treatment of COVID⁃19through combing, organizing and summarizing syndromes, treatment principles and methods, prescriptions and herbal medicines of “damp epidemic” in relevant TCM classics

目的 系统评价中西医结合治疗新型冠状病毒肺炎(简称“新冠肺炎”)的临床疗效.方法 计算机检索万方(WANFANG DATA)、中国知网(CNKI)、MEDLINE、Embase数据库,检索时间为自建库开始至2020年3月12日.根据Cochrane手册“偏倚风险”评估工具独立评估偏倚风险;采用纽卡斯尔-渥太华量表(NOS)进行非随机试验方法学质量评估,通过证据质量分级(GRADE)来衡量证据的质量;运用Review Manager 5.3软件对不同干预措施治疗新冠肺炎的结局指标进行Meta分析,比较治疗组(中西医结合治疗)与对照组(西医常规治疗)的临床疗效.结果 ①共纳入8个临床研究,包括804例病例.②其中1项研究为随机对照试验,4项研究为回顾性队列研究,另有自身前后对照研究1项、病例系列研究2项;5项研究纳入Meta分析,3项无对照组的研究仅出现在NOS评估中.③2项研究对重症转化率作了比较分析,结果提示治疗组的重症转化率低于对照组[RR=0.18,95％CI (0.04,0.79),P=0.02].④3项研究对临床治愈率作了比较分析,结果提示治疗组临床治愈率高于对照组[OR=7.82,95％CI(2.04,30.06),P=0.003].⑤2项研究对病死率作了分析,结果显示两组差异无统计学意义[RR=0.18,95％CI(0.01,4.23),P=0.29],无法得出异质性结论.⑥4项研究对发热时间作了比较分析,研究间存在明显异质性(Q统计量相应P值为0.003,I2=84％),结果提示治疗组退热疗效优于对照组[MD=-0.81,95％ CI(-1.53,-0.09),P=0.03],但需进一步分析其异质性的来源.⑦2项研究对症状积分作了比较分析,结果提示治疗组较对照组能更好地改善患者的临床症状[SMD=-0.84,95％CI(-1.25,-0.43),P＜0.000 1].⑧3项研究对咳嗽缓解率作了比较分析,结果提示治疗组较对照组能更好地改善患者的咳嗽症状[OR=5.14,95％CI(1.49,17.75),P=0.010].⑨3项研究对腹泻缓解率作了比较分析,结果显示两组差异无统计学意义[OR=1.19,95％ CI(0.17,8.64),P=0.86].⑩3项研究对肺炎吸收率作了比较分析,结果显示两组差异无统计学意义[RR=1.02,95％CI(0.85,1.22),P=0.87].结论 中西医结合治疗可降低新冠肺炎患者的重症转化率,提高临床治愈率,还在缓解咳嗽、退热等方面存在一定的优势.后续需要更多高质量的临床循证研究不断更新,才能完善本研究的证据完整性.

本文基于中医经典文献及临床实践思考,立足于“湿疫”理论阐释新型冠状病毒肺炎(简称“新冠肺炎”)的病因、病机、传变规律及治疗方药.认为新冠肺炎乃湿毒疫邪所致,其病机特点为内外病邪相引,合而致病;本病除遵循卫、气、营、血传变规律外,同时也表现出三焦传变的过程.同时,通过归纳梳理相关中医经典著作中关于湿疫的证治方药,为新冠肺炎的中医诊治提供临床思路.

从“肺与大肠相表里”角度,探讨肺肠同治在重型新型冠状病毒肺炎(COVID-19)临床诊疗中的意义.结合新型冠状病毒肺炎的发病特点及临床症状特点,认为胃肠道症状是除呼吸道症状外的又一主要表现,尤其在重型患者中,肺肠同治收效尤为明显.从中医理论、现代机制研究方面,阐述重型新冠肺炎患者肺肠同治的合理性与可行性.适用于重型新冠肺炎肺肠同治的代表方有承气汤类(包括大承气汤、小承气汤、调胃承气汤、宣白承气汤)、凉膈散、升降散等.

目的:研究温阳化饮通络法治疗肺源性心脏病急性加重期的临床疗效及对实验指标的影响.方法:将符合标准的肺源性心脏病急性加重患者80例随机分入观察组和对照组各40例.两组均予西医常规治疗,观察组加服加味小青龙汤.治疗1周及2周后分别对比疗效及相关指标.结果:治疗1周及2周后观察组总有效率分别为85％ 和92.5％,高于对照组的55％和72.5％(P<0.05);观察组治疗1周及治疗2周后脑钠肽、D-二聚体水平分别低于对照组(P<0.05,P<0.01;治疗1周后观察组中医症候总积分的改善优于对照组(P<0.01),中医症候各单项指标咳嗽、咯痰、喘促、胸闷心悸、浮肿、口唇青紫症状组间比较有统计学意义(P<0.05);治疗2周后两组中医症候总积分和中医症候各单项指标组间比较显著性差异(P>0.05).结论:温阳化饮通络法对肺源性心脏病急性加重患者具有显著疗效,在治疗早期即可明显改善患者症状及脑钠肽和二聚体的水平,中西医结合治疗可缩短疗程.

结合国内外中西医肺康复的研究成果,探讨重型/危重型新型冠状病毒肺炎机械通气患者的肺康复策略.机械通气是治疗重型/危重型肺炎必不可少的支持手段,但可能引起呼吸肌无力,导致痰液排泄障碍,进而影响预后.对于重型/危重型新型冠状病毒肺炎机械通气患者而言,及早采取必要的中西医肺康复干预措施意义重大,不仅有助于缓解呼吸困难症状,而且可缩短住院时间、改善预后.

目的:探索全蝎蜈蚣颗粒剂治疗顽固性感冒后咳嗽的临床疗效.方法:126例顽固性感冒后咳嗽患者被随机分配至对照组和观察组.对照组给予复方可待因口服液,观察组给予中药蝎蜈颗粒剂,治疗1周.比较两组治疗后临床疗效,咳嗽严重程度评分和咳嗽敏感性等项目.结果:观察组临床疗效优于对照组(P<0.05),两组治疗后咳嗽积分均较治疗前降低(P<0.05),观察组改善程度明显优于对照组(P<0.05).对照组治疗前后咳嗽敏感性无改善(P<0.05),而观察组治疗后咳嗽敏感性明显降低(P<0.05).结论:全蝎蜈蚣中药颗粒剂治疗顽固性感冒后咳嗽有显著的临床疗效.

背景:肺组织损伤修复过程中,细胞外基质成分首先填补损伤肺组织,当其过度沉积时可形成肺间质纤维化.目的:探讨肺痹方对博莱霉素致肺纤维化小鼠细胞外基质转化的干预作用.方法:将60只C57BL/6雄性小鼠随机分为空白对照组、模型组、吡非尼酮组、肺痹方低剂量组、肺痹方中剂量组、肺痹方高剂量组,每组10只.除空白对照组外,其余5组腹腔注射博莱霉素[7.5 mg/(kg·d)]建立肺纤维化模型,连续注射10 d.造模后第1天各药物组灌胃给药[51.43 mg/(kg·d)]吡非尼酮,6.43,12.86,25.72 mg/(kg·d)肺痹方],连续给药28 d.用药28 d后取肺组织,采用苏木精-伊红染色和Masson染色观察小鼠肺组织的形态学变化,ELISA法检测血清中转化生长因子β1、肿瘤坏死因子α水平,Western blot法检测肺组织中α-平滑肌肌动蛋白、Ⅰ型胶原、Ⅲ型胶原的表达.结果与结论:①与空白对照组相比,各组小鼠血清转化生长因子β1水平显著升高(P<0.01);与模型组相比,吡非尼酮组、肺痹方中剂量组、肺痹方高剂量组血清转化生长因子β1水平显著降低(P<0.05,P<0.01),肺痹方高剂量组降低最明显;②与模型组相比,用药各组血清肿瘤坏死因子α水平明显降低(P<0.01),用药各组之间两两比较差异无显著性意义(P>0.05);③与空白对照组相比,各组α-平滑肌肌动蛋白表达均不同程度增高(P<0.05,P<0.01);肺痹方高剂量组α-平滑肌肌动蛋白表达低于肺痹方低、中剂量组,差异有显著性意义(P<0.05);④与空白对照组相比,模型组、肺痹方低剂量组Ⅰ型胶原表达增高(P<0.05,P<0.01);与模型组相比,肺痹方中、高剂量组Ⅰ型胶原表达降低(P<0.05);⑤与空白对照组相比,各组Ⅲ型胶原表达均不同程度增高(P<0.05,P<0.01);肺痹方中、高剂量组以及吡非尼酮组Ⅲ型胶原表达明显低于肺痹方低剂量组(P<0.05,P<0.01);⑥结果表明,肺痹方可以减轻肺纤维化,抑制博来霉素诱导的肺纤维化小鼠细胞外基质转化,其机制可能与下调血清中转化生长因子 β1、肿瘤坏死因子 α 水平,抑制肺组织中 α-平滑肌肌动蛋白、Ⅰ型胶原、Ⅲ型胶原表达有关.